Please assess the completion status of the following clinical trial:

Trial Title: Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has had an original diagnosis of PCa and underwent radical curative therapy at least 3 months before enrolment, and has been diagnosed with biochemical recurrence (BCR) on the basis of:~  1. Post radical radiotherapy (RRT) / brachytherapy: Increase in PSA level ≥2.0 ng/mL above the nadir level after radiotherapy (RT) or brachytherapy (ASTRO-Phoenix criteria) \[53\], or~ 2. Post radical prostatectomy (RP): EITHER two consecutive rises in PSA and final PSA \>0.1ng/ml OR three consecutive rises in PSA., This definition is also applicable to subjects with PSA persistence post RP (where the PSA fails to fall to undetectable levels).~  i. In addition, the subject post RP, should have a PSA doubling time of ≤15 months OR PSA level ≥1.0 ng/mL at time of recruitment. The PSA doubling time will be calculated using the Memorial Sloan Kettering Cancer Center nomogram (http://www.mskcc.org/nomograms/prostate/psa-doubling-time), based on a minimum of two PSA levels within 12 months of screening, taken after the last recorded nadir PSA available at time of screening.~* The subject has not had previous recurrences of PCa, i.e. this is the first diagnosis of BCR.~* The subject is being considered for radical salvage therapy.~* The subject is able and willing to comply with study procedures, and signed, dated and timed informed consent is obtained before any study-related procedure is performed.~* The subject's Eastern Cooperative Oncology Group \[ECOG\] performance status 0-2.~* The subject should not have received androgen-deprivation therapy within 3 months of screening.~* The subject has a normal or clinically acceptable medical history and vital signs findings at screening (up to 14 days before administration of study drug).~Exclusion Criteria:~* The subject has been previously included in this study.~* The subject has received, or is scheduled to receive, another investigational medicinal product (IMP) from 1 month before to 1 week after administration of fluciclovine (18F) injection.~* The subject has known hypersensitivity to fluciclovine (18F) injection or any of its constituents.~* The subject has had a choline PET/CT scan within 3 months of the screening visit.~* The subject has bilateral hip prostheses.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm (Type: EXPERIMENTAL): Single intravenous administration of 18F-Fluciclovine for PET Scan

Based on this trial design, predict the completion outcome and termination type (if applicable).